FDA to Regulate E-Cigarettes, Hookahs

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the FDA that subject e-cigarettes and hookahs to some of the same regulations as tobacco products.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses new regulations from the US Food and Drug Administration for e-cigarettes and hookahs.

For example, the new rules would require a valid photo ID for purchasing e-cigarettes and hundreds of e-cigarette products will now require regulatory review in order to stay on the market.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Perioperative Enfortumab Vedotin Combo Has Potential as SOC in Cisplatin-Ineligible MIBC

Perioperative Enfortumab Vedotin Combo Has Potential as SOC in Cisplatin-Ineligible MIBC

Kristi Rosa
October 18th 2025
Article

Enfortumab vedotin plus pembrolizumab enhanced survival rates for patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Tiragolumab/Atezolizumab Does Not Meet PFS End Point in NSCLC

Jason M. Broderick
October 18th 2025
Article

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Adjuvant T-DXd Improves Efficacy vs T-DM1 in HER2-Positive Breast Cancer

Ashling Wahner
October 18th 2025
Article

T-DXd significantly improved iDFS compared with T-DM1 across various patient subgroups in high-risk, HER2-positive primary breast cancer with residual invasive disease.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

Adjuvant Nivolumab Improves Long-Term RFS vs Ipilimumab in Resected Melanoma

Kyle Doherty
October 18th 2025
Article

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.